Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Epizyme, Inc.EPZM · Entity 12703 | EVP & CFO | August 09, 2017 | August 10, 2017 |
| KYNTRA BIO, INC.KYNB · Entity 7431 | Director | October 01, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Epizyme, Inc.
Report date August 09, 2017 · Filed August 10, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Commons Stock, par value $0.0001SEC Table I · non-derivative | Direct | 45,446 |
Ending reported balance
After 2017-08-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-08-09 · Exercise / conversion · Acquired 1,682 · Balance 44,668 F1: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Row 2 · 2017-08-09 · Exercise / conversion · Acquired 778 · Balance 45,446 F1: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 30,274 |
Reported balance
After 2017-08-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-08-09 · Exercise / conversion · Disposed 1,682 · Balance 30,274 F1: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. F2: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 13,992 |
Reported balance
After 2017-08-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-08-09 · Exercise / conversion · Disposed 778 · Balance 13,992 F1: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. F3: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting.
F2: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person.
F3: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person.
KYNTRA BIO, INC.
Report date October 01, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.50 · Expires 2036-09-30 | Direct | 14,000 |
Reported balance
After 2026-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 14,000 · Balance 14,000 F1: The shares subject to the option shall vest in twelve equal quarterly installments measured from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest in twelve equal quarterly installments measured from the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 10, 2016 Filed Oct 12, 2016 13:42 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommon Stock, par value $0.0001 | 777 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-145682 · doc4.xml · nonDerivative · entry 2 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Read SEC document |
| October 10, 2016 Filed Oct 12, 2016 13:42 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommon Stock, par value $0.0001 | 1,682 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-145682 · doc4.xml · nonDerivative · entry 1 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Read SEC document |
| September 09, 2016 Filed Sep 12, 2016 20:18 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionRestricted Stock Units · Derivative | 777 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-140997 · doc4.xml · derivative · entry 5 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,543 Underlying: Common Stock · 777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. F5 · derivative.exercise_date: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. F5 · derivative.expiration_date: This award, granted on February 9, 2015, pursuant to the Company's 2013 Stock Inventive Plan, vests as to 25% of the total award on February 9, 2016, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. Read SEC document |
| September 09, 2016 Filed Sep 12, 2016 20:18 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionRestricted Stock Units · Derivative | 1,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-140997 · doc4.xml · derivative · entry 4 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,775 Underlying: Common Stock · 1,682 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. F4 · derivative.exercise_date: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. F4 · derivative.expiration_date: This award, granted on February 9, 2016, pursuant to the Company's 2013 Stock Incentive plan, vests as to 25% of the total award on February 9, 2016, a year from the commencement of employment, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter. Vested shares will be delivered to the reporting person. Read SEC document |
| September 09, 2016 Filed Sep 12, 2016 20:18 UTC | Epizyme, Inc. EPZM · Entity 12703 | SaleCommon Stock, par value $0.0001 | 1,013 | $7.55 | $7,651.19 |
DisclosureSEC source: 0001209191-16-140997 · doc4.xml · nonDerivative · entry 3 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,485 F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person to cover taxes associated with the vesting of his restricted stock. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 per share to $7.72 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 09, 2016 Filed Sep 12, 2016 20:18 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommon Stock, par value $0.0001 | 777 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-140997 · doc4.xml · nonDerivative · entry 2 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Read SEC document |
| September 09, 2016 Filed Sep 12, 2016 20:18 UTC | Epizyme, Inc. EPZM · Entity 12703 | Exercise / conversionCommon Stock, par value $0.0001 | 1,682 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-140997 · doc4.xml · nonDerivative · entry 1 Singer Andrew E. · CIK 0001632720 · EVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Epizyme, Inc. common stock upon vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.